维普中文期刊产品整合服务
29篇 您的检索式:作者名="Henry La"
    题名 作者 年代 出处 被引量
1Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy显示文摘AIM To determine influence of neoadjuvant-chemotherapy(NAC) over tumor-infiltrating-lymphocytes(TIL) intriple-negative-breast-cancer(TNBC).METHODS TILs were evaluated in 98 TNBC cases who came to Instituto Nacional de Enfermedades Neoplasicas from 2005 to 2010. Immunohistochemistry staining for CD3, CD4, CD8 and FOXP3 was performed in tissue microarrays(TMA) sections. Evaluation of H/E in full-face and immunohistochemistry in TMA sections was performed in pre and post-NAC samples. STATA software was used and P value < 0.05 was considered statistically significant. RESULTS Higher TIL evaluated in full-face sections from pre-NAC tumors was associated to pathologic-complete-response(pCR)(P = 0.0251) and outcome(P = 0.0334). TIL evaluated in TMA sections showed low level of agreement with full-face sections(ICC = 0.017-0.20) and was not associated to pCR or outcome. TIL in post-NAC samples were not associated to response or outcome. PostNAC lesions with pC R had similar TIL levels than those without pCR(P = 0.6331). NAC produced a TIL decrease in full-face sections(P < 0.0001). Percentage of TIL subpopulations was correlated with their absolute counts. Higher counts of CD3, CD4, CD8 and FOXP3 in pre-NAC samples had longer disease-free-survival(DFS). Higher counts of CD3 in pre-NAC samples had longer overallsurvival. Higher ratio of CD8/CD4 counts in pre-NAC was associated with pCR. Higher ratio of CD4/FOXP3 counts in pre-NAC was associated with longer DFS. Higher counts of CD4 in post-NAC samples were associated with pCR.CONCLUSION TIL in pre-NAC full-face sections in TNBC are correlated to longer survival. TIL in full-face differ from TMA sections, absolute count and percentage analysis of TIL subpopulation closely related.Carlos A Castaneda Elizabeth Mittendorf Sandro Casavilca Yun Wu Miluska Castillo Patricia Arboleda Teresa Nunez Henry Guerra Carlos Barrionuevo Ketty Dolores-Cerna Carolina Belmar-Lopez Julio Abugattas Gabriela Calderon Miguel De La Cruz Manuel Cotrina Jorge Dunstan Henry L Gomez Tatiana Vidaurre 2016World Journal of Clinical Oncology2016,7,5:6
2New therapeutic opportunities for Hepatitis C based on small RNA显示文摘Hepatitis C virus (HCV) infection is one of the major causes of chronic liver disease, including cirrhosis and liver cancer and is therefore, the most common indication for liver transplantation. Conventional antiviral drugs such as pegylated interferon-alpha, taken in combination with ribavirin, represent a milestone in the therapy of this disease. However, due to different viral and host factors, clinical success can be achieved only in approximately half of patients, making urgent the requirement of exploiting alternative approaches for HCV therapy. Fortunately, recent advances in the understanding of HCV viral replication and host cell interactions have opened new possibilities for therapeutic intervention. The most recent technologies, such as small interference RNA mediated gene-silencing, anti-sense oligonucleotides (ASO), or viral vector based gene delivery systems, have paved the way to develop novel therapeutic modalities for HCV. In this review, we outline the application of these technologies in the context of HCV therapy. In particular, we will focus on the newly defined role of cellular microRNA (miR-122) in viral replication and discuss its potential for HCV molecular therapy.Qiu-wei Pan Scot D Henry Bob J Scholte Hugo W Tilanus Harry LA Janssen Luc JW van der Laan 2007World Journal of Gastroenterology2007,13,33:4
3Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy显示文摘AIM To investigate the survival impact of clinicopathological factors, including pathological complete response(p CR) and tumor-infiltrating lymphocytes(s TIL) levels according to subtypes, in breast cancer(BC) patients who received neo-adjuvant chemotherapy(NAC).METHODS We evaluated 435 BC patients who presented and received NAC at the Instituto Nacional de Enfermedades Neoplasicas from 2003 to 2014. s TIL was analyzed as the proportion of tumor stroma occupied by lymphocytes, and was prospectively evaluated on hematoxylin and eosin-stained sections of the preN AC core biopsy. p CR was considered in the absence of infiltrating cancer cells in primary tumor and axillary lymph nodes. Analysis of statistical association between clinical pathological features, s TIL, p CR and survival were carried out using SPSSvs19.RESULTS Median age was 49 years(range 24-84 years) and the most frequent clinical stage was ⅢB(58.3%). Luminal A, Luminal B, HER2-enriched and(triple-negative) TN phenotype was found in 24.6%, 37.9%, 17.7% and 19.8%, respectively. p CR was observed in 11% and median percentage of s TIL was 40%(2%-95%) in the whole population. p CR was associated to Ct1-2(P = 0.045) and to high s TIL(P = 0.029) in the whole population. There was a slight trend towards significance for s TIL(P = 0.054) in Luminal A. s TIL was associated with grade Ⅲ(P < 0.001), no-Luminal A subtype(P < 0.001), RE-negative(P < 0.001), PgR-negative(P < 0.001), HER2-positive(P = 0.002) and p CR(P = 0.029) in the whole population. Longer disease-free survival was associated with grade Ⅰ-Ⅱ(P = 0.006), cN 0(P < 0.001), clinical stage Ⅱ(P = 0.004), ER-positive(P < 0.001), Pg R-positive(P < 0.001), luminal A(P < 0.001) and p CR(P = 0.002). Longer disease-free survival was associated with grade Ⅰ-Ⅱ in Luminal A(P < 0.001), N0-1 in Luminal A(P = 0.045) and TNBC(P = 0.01), clinical stage Ⅱ in Luminal A(P = 0.003) and TNBC(P = 0.038), and pC R in TNBC(P < 0.001). Longer overall survival was associated with grade Ⅰ-Ⅱ(P < 0.001), ER-positive(P < 0.001), PgR-positive(P < 0.001), Luminal A(P < 0.001), cN 0(P = 0.002) and p CR(P = 0.002) in the whole population. Overall survival was associated with clinical stage Ⅱ(P = 0.017) in Luminal A, older age(P = 0.042) in Luminal B, and pC R in TNBC(P = 0.005).CONCLUSION Predictive and prognostic values of clinicopathological features, like p CR and s TIL, differ depending on the evaluated molecular subtype.Marco Galvez Carlos A Castaneda Joselyn Sanchez Miluska Castillo Lia Pamela Rebaza Gabriela Calderon Miguel De La Cruz Jose Manuel Cotrina Julio Abugattas Jorge Dunstan Henry Guerra Omar Mejia Henry L Gomez 2018World Journal of Clinical Oncology2018,9,2:4
4Tracheobronchial involvement with Crohn's disease 显示文摘Henry MT Davidson LA Cooke NJ 2001Eur J Gastroenterol Hepatol2001,13,12:1
5Techniques and Training with GreenLight HPS 120-W Laser Therapy of the Prostate: Position Paper显示文摘Gordon Muir Fernando Gómez Sancha Alexander Bachmann Benjamin Choi Edward Collins Jean de la Rosette Oliver Reich Shahin Tabatabaei Henry Woo 2007European Urology Supplements2007,,:1
6Biodiversity and ecological composition of macrobenthos on cold-water coral mounds and adjacent off?mound habitat in the bathyal Porcupine Seabight, NE Atlantic显示文摘Henry LA RobertsJ M 2007Deep Sea Research Part I2007,54,65:1
7Working memory span and phonological awareness tasks as predictors of early reading ability显示文摘Fletcher PC Henry LA 1994Journal of Experimental Child Psychology1994,58,:1
8Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs:results of a collaborative meta-analysis显示文摘Henry D Lim LL Garcia Rodriguez LA 1996BMJ1996,312,7046:1
9Resveratrol: phytoestrogen effects on reproductive physiology and behavior in female rats显示文摘Henry LA Witt DM 2002Horm Behav2002,41,2:1
10药物代金券对P2Y12抑制剂使用和心肌梗死患者主要不良心血管事件的影响:ARTEMIS随机临床试验显示文摘尽管有指南推荐,但许多患者比心肌梗死后推荐的1年更早停止P2Y12抑制剂治疗,并且未充分利用更高效的P2Y12抑制剂。医药成本经常被用来解释这两种观察结果。本研究旨在确定药物代金券是否会增加P2Y12抑制剂持久性使用,并降低主要不良心血管事件(major adverse cardiovascular events,MACE)的风险。在收治成人急性心肌梗死患者的301家医院中进行集群随机临床试验(2015年6月5日至2016年9月30日);患者出院后随访1年(随访截止日期为2017年10月23日),对MACE进行盲法判定;根据临床医生的判断,选择是否使用P2Y12抑制剂。刘青 叶鹏 Wang TY Kaltenbach LA Cannon CP Fonarow GC Choudhry NK Henry TD Cohen DJ Bhandary D Khan ND Anstrom KJ Peterson ED 2019中华高血压杂志2019,27,2:1
11Acute retinal ischemia caused by controlled low ocular perfusion pressure in a porcine model. Electrophysiological and histological characterisation显示文摘Maria Voss Kyhn Karin Warfvinge Erik Scherfig Jens F. Kiilgaard Jan Ulrik Prause Henry Klassen Michael Young Morten la Cour 2009Experimental Eye Research2009,,6:1
12Executive function in Williams and Down syndromes显示文摘Carney DP Brown JH Henry LA 2013Res Dev Disabil2013,34,1:1
13Interactions between human CO2 chemoreflexes and arterial baroreflexes显示文摘Henry RA Lu I - L Beightol LA and Eckberg DL 1998A m J Physiol1998,274,:1
14Role of CD4 and CD8 T-lymphocytes, B-lyrnphocytes and Natural Kil- ler cells in the prediction of radiation-induced late toxicity in cer- vical cancer patients显示文摘Bord6n E Henri quez-Hernd ndez LA Lara PC 2011Int J Radiat Biol2011,87,4:1
15Sdective toxicity of dihydroanemisinin and holotransferrin toward human breast cancer cells显示文摘Narendra P Singh Henry La 2001Life Science2001,70,1:1
16Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis显示文摘Boven LA Verguolle N Henry SD 2003J Immunol2003,170,5:1
17Effects of neonatal resveratrol exposure on adult male and female reproductive physiology and behavior 显示文摘Henry LA Witt DM 2006Dev Neurosci2006,28,3:1
18The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy显示文摘Adil Ouzzane Pierre Colin Tarek P. Ghoneim Marc Zerbib Alexandre De La Taille Fran?ois Audenet Fabien Saint Nicolas Hoarau Emilie Adam Marie Dominique Azemar Henri Bensadoun Luc Cormier Olivier Cussenot Alain Houlgatte Gilles Karsenty Charlotte Maurin Fra 2013World Journal of Urology2013,,1:1
19Analyzing morpho-genetic cell behaviors in vitally stained zebrafish embryos 显示文摘Cooper MS D'Amico LA Henry CA 1999Methods Mol Biol1999,122,:1
20Amifos- tine modulates radio-induced apoptosis of peripheral blood lympho- cytes in head and neck cancer patients显示文摘Saavedra MM Henri quez-Hema ndez LA Lara PC 2010J Radiat Res (Tokyo)2010,51,5:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费